Rencent Capital pursues long-term structural value investment and looks for industry pioneers with long-term competitiveness. Through the thorough understanding of China's macro and micro economic trends and comprehensive analysis of the global market situation, Rencent Capital focuses on leading enterprises with unique competitive advantage in fields such as medical health, scientific and technological innovation and consumption, providing financial support at all stages from start-up to post-IPO. The investment category includes fund investment and direct equity investment.

Rencent Capital builds a diversified growth portfolio based on global macro risk hedging, reaches deep cooperation with internationally renowned investment banks such as Morgan Stanley, Goldman Sachs, UBS and participates in the overseas markets, Rencent Capital is the strategic partner of well-known institutions including Sequoia Capital, Hillhouse Capital, Firstred Capital, CICC Capital and CDH Venture Capital.

Rencent Capital has invested in many high potential companies with distinct technology and innovative business model, also with high growth and return potential. The portfolio includes ByteDance, CALB, BYD semiconductor, E-Town Semiconductor, Smarter micro，Clounix, Cloudwis，pingCAP, xingshengyouxuan,JDL, YMM, Huolala，zhuanzhuan，i-mabbiopharma ，BioNova Pharmaceuticals, Haihe Biopharma, ClinChoice and other outstanding enterprises.